Deciphering Distinct Genetic Risk Factors for FTLD-TDP

2 Pathological Subtypes via Whole-Genome Sequencing

3 Cyril Pottier^{1,2,3,4,5,*}, Fahri Küçükali^{2,3}, Matt Baker¹, Anthony Batzler⁶, Gregory D. Jenkins⁶, Marka van Blitterswijk¹, Cristina T. Vicente^{2,3}, Wouter De Coster^{2,3}, Sarah Wynants^{2,3}, Pieter 4 Van de Walle^{2,3}, Owen A. Ross¹, Melissa E. Murray¹, Júlia Faura^{2,3}, Stephen J. Haggarty⁷, 5 Jeroen GJ. van Rooij⁸, Merel O. Mol⁸, Ging-Yuek R. Hsiung⁹, Caroline Graff^{10,11}, Linn 6 Öijerstedt^{10,11}, Manuela Neumann^{12,13}, Yan Asmann¹⁴, Shannon K. McDonnell⁶, Saurabh 7 Baheti⁶, Keith A. Josephs¹⁵, Jennifer L. Whitwell¹⁶, Kevin F. Bieniek^{1,17}, Leah Forsberg¹⁵, 8 Hilary Heuer¹⁸, Argentina Lario Lago¹⁸, Ethan G. Geier¹⁸, Jennifer S. Yokoyama¹⁸, Alexis P. 9 Oddi¹⁸, Margaret Flanagan¹⁷, Qinwen Mao¹⁹, John R. Hodges²⁰, John B. Kwok^{21,22}, Kimiko 10 Domoto-Reilly²³, Matthis Synofzik^{12,24}, Carlo Wilke^{12,24}, Chiadi Onyike²⁵, Bradford C. 11 Dickerson²⁶, Bret M. Evers²⁷, Brittany N. Dugger²⁸, David G. Munoz^{29,30}, Julia Keith^{30,31}, 12 Lorne Zinman³¹, Ekaterina Rogaeva³², EunRan Suh³³, Tamar Gefen³⁴, Changiz Geula³⁴, 13 Sandra Weintraub³⁴, Janine Diehl-Schmid^{35,36}, Martin R. Farlow³⁷, Dieter Edbauer³⁸, Bryan K. 14 Woodruff³⁹, Richard J. Caselli³⁹, Laura L. Donker Kaat⁴⁰, Edward D. Huey⁴¹, Eric M. 15 Reiman⁴², Simon Mead⁴³, Andrew King^{44,45}, Sigrun Roeber⁴⁶, Alissa L. Nana¹⁸, Nilufer 16 Ertekin-Taner^{1,47}, David S. Knopman¹⁵, Ronald C. Petersen¹⁵, Leonard Petrucelli¹, Ryan J. 17 Uitti⁴⁷, Zbigniew K. Wszolek⁴⁷, Eliana Marisa Ramos⁴⁸, Lea T. Grinberg¹⁸, Maria Luisa Gorno 18 Tempini¹⁸, Howard J. Rosen⁴⁹, Salvatore Spina¹⁸, Olivier Piguet⁵⁰, Murray Grossman⁵¹, John 19 Q. Trojanowski³³, Dirk C. Keene⁵², Jin Lee-Way⁵³, Johannes Prudlo^{54,55}, Daniel H. 20 Geschwind⁴⁸, Robert A. Rissman⁵⁶, Carlos Cruchaga⁵⁷, Bernardino Ghetti⁵⁸, Glenda M. 21 Halliday²¹, Thomas G. Beach⁵⁹, Geidy E. Serrano⁵⁹, Thomas Arzberger^{46,60}, Jochen Herms^{38,46}, 22 Adam L. Boxer¹⁸, Lawrence S. Honig⁶¹, Jean P. Vonsattel⁶², Oscar L. Lopez⁶³, Julia Kofler⁶⁴, 23 Charles L. White III²⁷, Marla Gearing⁶⁵, Jonathan Glass⁶⁵, Jonathan D. Rohrer⁶⁶, David J. 24 Irwin⁵¹, Edward B. Lee³³, Vivianna Van Deerlin³³, Rudolph Castellani⁶⁷, Marsel M. 25 Mesulam³⁴, Maria C. Tartaglia³², Elizabeth C. Finger⁶⁸, Claire Troakes⁴⁴, Safa Al-Sarraj^{44,69}, 26 Bruce L. Miller¹⁸, Harro Seelaar⁸, Neill R. Graff-Radford⁴⁷, Bradley F. Boeve¹⁵, Ian RA. 27 Mackenzie⁷⁰, John C. van Swieten⁸, William W. Seeley¹⁸, Kristel Sleegers^{2,2}, Dennis W. 28 Dickson¹, Joanna M. Biernacka^{6,71}, Rosa Rademakers^{1,2,3,*} 29

³⁰

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

31 † In memoriam

32 * Corresponding Authors

- 33 Rosa Rademakers, Ph.D. (ORCID: 0000-0002-4049-0863)
- 34 VIB Center for Molecular Neurology
- 35 Universiteitsplein 1, 2610 Wilrijk, Belgium
- 36 Phone: +32 3 265 95 95
- 37 E-mail: <u>rosa.rademakers@uantwerpen.vib.be</u>
- 38
- 39 Cyril Pottier, Ph.D.
- 40 Department of Neurology, Washington University School of Medicine
- 41 St Louis, MO, United States of America
- 42 Phone: +1 314 747 2601
- 43 E-mail: cpottier@wustl.edu
- 44
- ¹Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224,
- 46 United States of America
- ⁴⁷ ²Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium
- 48 ³VIB Center for Molecular Neurology, VIB, Antwerp, Belgium
- ⁴Department of Neurology, Washington University School of Medicine, St Louis, MO,
- 50 United States of America
- ⁵NeuroGenomics and Informatics Center, Washington University School of Medicine, St
- 52 Louis, MO, United States of America
- ⁶Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, 55905, United
- 54 States of America
- ⁷Department of Neurology, Massachusetts General Hospital and Harvard Medical School,

- 56 Boston, MA, 02114, United States of America
- ⁸Department of Neurology, Erasmus Medical Center, Wytemaweg 80, Rotterdam, 3015 CN,
- 58 The Netherlands
- ⁹Department of Medicine, Division of Neurology, University of British Columbia,
- 60 Vancouver, BC, V6T 2B5, Canada
- ¹⁰Division of Neurogeriatrics, Karolinska Institutet, Bioclinicum J10:20, Visionsgatan 4,
- 62 Solna, 171 64, Sweden
- ⁶³ ¹¹Unit for Hereditary Dementias, Karolinska University Hospital, Solna, 171 64, Sweden
- ¹²German Center for Neurodegenerative Diseases (DZNE), Tübingen, 72076, Germany
- ¹³Department of Neuropathology, University of Tübingen, Tübingen, 72076, Germany
- ¹⁴Department of Health Sciences Research, Mayo Clinic, 4500 San Pablo Road, Jacksonville,
- 67 FL, 32224, United States of America
- ¹⁵Department of Neurology, Mayo Clinic, Rochester, MN, 55905, United States of America
- ⁶⁹ ¹⁶Department of Radiology, Mayo Clinic, Rochester, MN, 55905, United States of America
- ¹⁷University of Texas Health Science Center San Antonio, San Antonio, TX, 78229, United
- 71 States of America
- ¹⁸Department of Neurology, UCSF Weill Institute for Neurosciences, University of
- 73 California, San Francisco, San Francisco, CA, 94158, United States of America
- ¹⁹Department of Pathology, University of Utah, Salt Lake City, UT, 84112, United States of
- 75 America
- ²⁰Central Clinical School and Brain and Mind Centre, University of Sydney, Sydney, 2050,
- 77 Australia
- ²¹University of Sydney, Sydney, 2050, Australia
- ²²NeuRA, University of New South Wales, Randwick, 2031, Australia
- ²³Department of Neurology, University of Washington, 325 9th Ave, Seattle, WA, 98104,
- 81 United States of America
- ²⁴Division Translational Genomics of Neurodegenerative Diseases, Center for Neurology and
- 83 Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany
- ²⁵Department of Psychiatry and Behavioral Sciences, Johns Hopkins University, Baltimore,
- MD, 21218, United States of America
- ²⁶Department of Neurology, Case Western Reserve University, Cleveland, OH, 44106,
- 87 United States of America
- 88 ²⁷Division of Neuropathology, University of Texas Southwestern Medical Center, 5323 Harry
- 89 Hines Blvd, Dallas, TX, 75390-9073, United States of America

- ²⁸Department of Pathology and Laboratory Medicine, University of California, Davis
- 91 Medical Center, Sacramento, CA, 95817, United States of America
- 92 ²⁹St. Michael's Hospital, 30 Bond St, Toronto, ON, M5B 1W8, Canada
- ³⁰Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto,
- 94 ON, M5S 1A1, Canada
- 95 ³¹Sunnybrook Health Sciences Centre, Toronto, ON, M4N 3M5, Canada
- ³²Krembil Discovery Tower, Tanz Centre for Research in Neurodegenerative Disease,
- 97 University of Toronto, 60 Leonard Av, Toronto, ON, M5T 0S8, Canada
- 98 ³³Department of Pathology and Laboratory Medicine, Center for Neurodegenerative Disease
- 99 Research, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA,
- 100 19104, United States of America
- ³⁴Mesulam Center for Cognitive Neurology and Alzheimer's Disease, Northwestern
- 102 University, Chicago, IL, 60611, United States of America
- ³⁵Department of Psychiatry and Psychotherapy, Technical University of Munich, Munich,
- 104 80333, Germany
- ³⁶kbo-Inn-Salzach-Klinikum, Clinical Center for Psychiatry, Psychotherapy, Psychosomatic
- 106 Medicine, Geriatrics and Neurology, Wasserburg/Inn, 83512, Germany
- ³⁷Department of Neurology, Indiana University School of Medicine, 355 West 16th Street,
- 108 Indianapolis, IN, 46202, United States of America
- ³⁸German Center for Neurodegenerative Diseases (DZNE), Feodor-Lynen-Str 17, Munich,
- 110 81377, Germany
- ³⁹Department of Neurology, Mayo Clinic, Scottsdale, AZ, 85259, United States of America
- ⁴⁰Department of Clinical Genetics, Erasmus Medical Center, Wytemaweg 80, Rotterdam,
- 113 3015 CN, The Netherlands
- ⁴¹Department of Psychiatry and Human Behavior, Brown Alpert Medical School, Brown
- 115 University, Providence, RI, 02912, United States of America
- ⁴²Banner Alzheimer's Institute, Phoenix, AZ, 85006, United States of America
- ⁴³MRC Prion Unit at University College London, Institute of Prion Diseases, London, United
- 118 Kingdom
- ⁴⁴Department of Basic and Clinical Neuroscience, London Neurodegenerative Diseases Brain
- 120 Bank, Institute of Psychiatry, Psychology and Neuroscience, King's College London,
- 121 London, SE5 8AF, United Kingdom
- ⁴⁵Department of Clinical Neuropathology, King's College Hospital NHS Foundation Trust,
- 123 London, SE5 9RS, United Kingdom

- ⁴⁶Centre for Neuropathology and Prion Research, Ludwig-Maximilians-University of
- 125 Munich, Feodor-Lynen-Straße 23, Munich, 81377, Germany
- ⁴⁷Department of Neurology, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224,
- 127 United States of America
- ⁴⁸Department of Neurology, David Geffen School of Medicine, University of California, Los
- 129 Angeles, Los Angeles, CA, 90095, United States of America
- ⁴⁹Department of Pathology, UCSF Weill Institute for Neurosciences, University of
- 131 California, San Francisco, San Francisco, CA, 94158, United States of America
- ⁵⁰School of Psychology and Brain and Mind Centre, University of Sydney, Sydney, 2050,
- 133 Australia
- ⁵¹Department of Neurology, Penn Frontotemporal Degeneration Center, Perelman School of
- 135 Medicine at the University of Pennsylvania, Philadelphia, PA, 19104, United States of
- 136 America
- ⁵²University of Washington BioRepository and Integrated Neuropathology (BRaIN) lab,
- 138 Harborview Medical Center, 325 9th Ave, Seattle, WA, 98104, United States of America
- ⁵³M.I.N.D. Institute Laboratory, University of California, Davis Medical Center, 2805 50th
- 140 St, Sacramento, CA, 95817, United States of America
- ⁵⁴German Center for Neurodegenerative Diseases (DZNE), Rostock, 18147, Germany
- ⁵⁵Department of Neurology, Rostock University Medical Center, Rostock, 18147, Germany
- ⁵⁶Alzheimer's Therapeutic Research Institute, Keck School of Medicine of the University of
- 144 Southern California, San Diego, CA, USA
- ⁵⁷Department of Psychiatry, Knight Alzheimer Disease Research Center, Washington
- 146 University School of Medicine, Saint Louis, MO, 63108, United States of America
- ⁵⁸Department of Pathology and Laboratory Medicine, Indiana University School of Medicine,
- 148 635 Barnhill Drive, Indianapolis, IN, 46202, United States of America
- ⁵⁹Civin Laboratory for Neuropathology, Banner Sun Health Research Institute, Sun City, AZ,
- 150 85351, United States of America
- ⁶⁰Department of Psychiatry and Psychotherapy, University Hospital, Ludwig-Maximilians-
- 152 University of Munich, Munich, 81377, Germany
- ⁶¹Department of Neurology, Taub Institute for Research on Alzheimer's Disease and the
- 154 Aging Brain, Columbia University Irving Medical Center, 630 West 168th St, New York,
- 155 NY, 10032, United States of America
- ⁶²Department of Pathology, Taub Institute for Research on Alzheimer's Disease and the
- 157 Aging Brain, Columbia University Irving Medical Center, 630 West 168th St, New York,

- 158 NY, 10032, United States of America
- ⁶³Department of Neurology, University of Pittsburgh, Pittsburgh, PA, 15213, United States of
- 160 America
- ⁶⁴Department of Pathology, University of Pittsburgh, Pittsburgh, PA, 15213, United States of
- 162 America
- ⁶⁵Department of Pathology and Laboratory Medicine and Department of Neurology, Emory
- 164 University, Atlanta, GA, 30322, United States of America
- ⁶⁶Department of Neurodegenerative Disease, Dementia Research Centre, University College
- 166 London Queen Square Institute of Neurology, London, WC1N 3BG, United Kingdom
- ⁶⁷Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago,
- 168 IL, 60611, United States of America
- ⁶⁸Department of Clinical Neurological Sciences, Schulich School of Medicine and Dentistry,
- 170 University of Western Ontario, London, ON, N6A 2E2, Canada
- ⁶⁹King's College Hospital NHS Foundation Trust, London, SE5 9RS, United Kingdom
- ¹⁷² ⁷⁰Department of Pathology and Laboratory Medicine, University of British Columbia,
- 173 Vancouver, BC, V6T 1Z7, Canada
- ⁷¹Department of Psychiatry & Psychology, Mayo Clinic, Rochester, MN, 55905, United
- 175 States of America
- 176
- 177

178 Abstract

Frontotemporal lobar degeneration with neuronal inclusions of the TAR DNA-binding protein 179 180 43 (FTLD-TDP) is a fatal neurodegenerative disorder with only a limited number of risk loci 181 identified. We report our comprehensive genome-wide association study as part of the 182 International FTLD-TDP Whole-Genome Sequencing Consortium, including 985 cases and 3,153 controls, and meta-analysis with the Dementia-seq cohort, compiled from 26 183 184 institutions/brain banks in the United States, Europe and Australia. We confirm UNC13A as the strongest overall FTLD-TDP risk factor and identify *TNIP1* as a novel FTLD-TDP risk 185 186 factor. In subgroup analyses, we further identify for the first time genome-wide significant loci

- 187 specific to each of the three main FTLD-TDP pathological subtypes (A, B and C), as well as
- 188 enrichment of risk loci in distinct tissues, brain regions, and neuronal subtypes, suggesting
- 189 distinct disease aetiologies in each of the subtypes. Rare variant analysis confirmed *TBK1* and
- 190 identified *VIPR1*, *RBPJL*, and *L3MBTL1* as novel subtype specific FTLD-TDP risk genes,
- 191 further highlighting the role of innate and adaptive immunity and notch signalling pathway in
- 192 FTLD-TDP, with potential diagnostic and novel therapeutic implications.

193

194

195 **Main**

196 Introduction

Frontotemporal lobar degeneration (FTLD) is one of the leading causes of dementia in 197 198 individuals younger than 65 years but can also affect individuals later in life. The predominant 199 clinical presentations of FTLD are behavior and language dysfunction resulting in behavioral 200 variant frontotemporal dementia (bvFTD)¹, semantic variant primary progressive aphasia (svPPA), or nonfluent variant primary progressive aphasia (nfvPPA)². The diagnosis of FTLD 201 can be established with certainty only with neuropathologic postmortem examination and is 202 203 characterized neuropathologically with significant atrophy of the frontal and temporal lobes 204 and accumulation of abnormal neuronal and/or glial inclusions upon immunohistochemical 205 analysis. FTLD-TDP, characterized by neuronal and cytoplasmic aggregates of the DNA and 206 RNA-binding protein TDP-43, is one of the two main pathological subtypes (the other being 207 FTLD-Tau) and can be further classified into five FTLD-TDP subtypes (FTLD-TDP A-E) 208 based on the distribution of the neuronal cytoplasmic TDP-43-positive inclusions and dystrophic neurites in the cortical layers^{3,4}. In general, an accurate prediction of the underlying 209 210 neuropathological FTLD subtype of individual patients constitutes a diagnostic challenge; 211 however, a few clinicopathological correlations exist. Specifically, over 80% of patients clinically presenting with svPPA are diagnosed as FTLD-TDP C at autopsy⁵, and patients with 212 213 bvFTD with concomitant amyotrophic lateral sclerosis (ALS) almost invariably present as FTLD-TDP B at $autopsy^{2,4,6}$. 214

A small number of autosomal dominant genes and risk factors associated with FTLD-TDP have been reported⁷⁻¹³. The first FTLD-TDP genome-wide association study (GWAS) identified the *TMEM106B* locus (rs1990622), supporting lysosomal dysfunction in FTLD-TDP; however, this signal was strongly driven by *GRN* mutation carriers included in that study. Three

additional FTLD-TDP loci, *UNC13A*, *DPP6* and *HLA-DQA2*, were identified in phase I of the
International FTLD-TDP whole-genome sequencing (WGS) consortium and require
replication in larger datasets¹¹. Importantly, most FTLD-TDP patients are not yet genetically
explained, and the relatively small sample size precluded rare variant analyses in phase I.

223 To replicate and identify new genetic risk factors, we doubled the original sample size of the 224 FTLD-TDP WGS consortium by not only sequencing more pathologically confirmed FTLD-225 TDP cases but also including clinically defined FTLD subtypes enriched for specific FTLD-226 TDP pathological subtypes at autopsy. GWAS analyses of both common and rare variants, 227 followed by comprehensive gene-prioritization, enrichment analyses, and co-localization 228 studies identified novel FTLD-TDP risk loci, including novel risk genes and loci specific to 229 FTLD-TDP pathological subtypes. Our study highlights similarities and differences between 230 FTLD-TDP and other neurodegenerative diseases while unique biological processes in specific 231 tissues, brain regions, and cell types were found to characterize individual FTLD-TDP 232 pathological subtypes.

233

234 **Results**

235 **GWAS analysis**

236 Common variant genome-wide association study

To identify novel common FTLD-TDP genetic risk factors, we performed single variant GWAS using an additive disease risk model for 6,568,099 common variants in 985 patients and 3,153 controls free of neurodegenerative disorder that passed quality control (QC). Combining all patients (FTLD-TDP All) we identified one genome-wide significant signal at the *UNC13A* locus (rs8111424, OR=1.37, P=1.17x10⁻⁸). We also performed separate GWAS within the FTLD-TDP A, FTLD-TDP B, and FTLD-TDP C pathological subtypes (**Fig. 1**,

243 Tables 1-2). The most significant locus identified in FTLD-TDP A was GRN (rs5848; OR=1.89, $P=5.57 \times 10^{-9}$). In phase I, this locus only reached genome-wide significance under 244 an exploratory recessive model¹¹, and also now, the recessive model provided an even stronger 245 association (OR=4.12, $P=8.28 \times 10^{-15}$). We further detected 3 additional new genome-wide 246 247 significant loci in FTLD-TDP A: TINAG (rs138698596), MZT1 (rs138959102) and FARP2 248 (rs886815). In FTLD-TDP B, we detected a genome-wide significant association at the 249 UNC13A locus (rs12973192). The lead variant rs12973192 is in linkage disequilibrium (LD) with rs8111424 (D'=1; $r^2=0.43$) identified in the FTLD-TDP All analysis. We further detected 250 3 new genome-wide significant risk loci in FTLD-TDP B: TNIP1 (rs871269), RCL1 251 (rs7674221), PDS5B (rs5277499), and one in FTLD-TDP C C19orf52 (also known as 252 253 TIMM29, rs576561313).

In order to prioritize risk genes and identify possible biological mechanisms, we applied a range of variant annotation and molecular quantitative trait loci (QTL)-GWAS integration analyses as previously described¹⁴ (**Supplementary Tables 2-13**). We integrated different levels of evidence using a weighting scheme and obtained a weighted sum of the hits in different subcategories for each gene. We grouped candidate risk genes in genome-wide significant loci and in subthreshold loci and prioritized them at two levels of confidence for being a likely risk gene as tier 1 (higher confidence) and tier 2 (lower confidence).

The gene prioritization analyses nominated a total of 59 tier 1 and 246 tier 2 genes in 258 different loci for 4 different GWAS analyses (**Fig. 2, Supplementary Table 3, Supplementary Fig. 2-5**). Our results showed that the nearest protein-coding genes were prioritized as tier 1 (n=8) and tier 2 (n=1) risk genes in the genome-wide significant loci for the distinct FTLD-TDP subtypes. Of the 8 tier 1 prioritized genes, 3 were found in common variant loci where molecular QTL-GWAS analyses aided their prioritization (**Fig. 2**). First, in locus A4, *GRN* was prioritized through consistent expression QTL (eQTL) domain hits in bulk

brain regions (eOTL PROSMAP DLPFC=6.32x10⁻³⁸ and betaROSMAP DLPFC=-0.25, eQTL 268 269 colocalization (coloc) PPH4s of 81.8%-99.7%, and fine-mapped [posterior inclusion 270 probability being 100%] expression transcriptome wide association study [eTWAS] associations with P from 1.74×10^{-8} to 5.15×10^{-9} and Z-scores from -5.63 to -5.84) and in 271 272 oligodendrocytes (cell type specific eQTL (ct-eQTL) coloc PPH4=90%) where genetic 273 downregulation of GRN gene expression was associated with the FTLD-TDP A risk signal 274 (Supplementary Tables 5, 6, and 11), which was also observed in brain proteome-wide 275 association study (PWAS) with the same effect direction for the FTLD-TDP A risk (PROSMAP 276 $DLPFC = 3.32 \times 10^{-6}$, $Z_{ROSMAP DLPFC} = -4.65$, Supplementary Table 13). Second, in locus B1, 277 TNIP1 was prioritized because the minor allele was associated with decreased TNIP1 278 expression ($P_{\text{ROSMAP DLPFC}} = 2.40 \times 10^{-4}$, beta_{\text{ROSMAP DLPFC}} = -0.10), the GWAS signal colocalized 279 with a microglia splicing QTL (sQTL) associated with TNIP1 chr5:151032383-151035002 280 known splice junction (coloc PPH4=82.2%) and because the methylation QTL (mQTL) 281 variants for cg03340667, a CpG ~3.7 kb upstream of the transcription start site (TSS) of the 282 canonical transcript of TNIP1, colocalized with the GWAS variants (coloc PPH4=70%) in 283 dorsolateral prefrontal cortex (DLPFC) (Supplementary Tables 5, 7, and 8). Third, in locus 284 B4, UNC13A was prioritized through an eQTL-GWAS colocalization in temporal cortex (coloc PPH4=81.82%, Supplementary Table 6). Furthermore, beyond genome-wide significant loci, 285 286 we identified additional candidate prioritized risk genes in subthreshold regions through 287 molecular QTL-GWAS coloc and TWAS analyses, one important example being TMEM106B 288 as the prioritized risk gene in locus A_S14. The FTLD-TDP A GWAS signal near TMEM106B 289 colocalized with eQTL variants regulating *TMEM106B* gene expression in bulk brain regions 290 (eQTL coloc PPH4s=81.40% in MayoRNASeq temporal cortex and 89.66% in GTEx brain 291 cortex, **Supplementary Table 6**). We also observed a significant eTWAS association in GTEx 292 cortex ($P=4.13 \times 10^{-7}$, Z=-5.06), together with a significant PWAS hit ($P=2.01 \times 10^{-8}$,

293 Zscore=5.61) (Supplementary Tables 11, 13). Finally, a significant hit in splicing TWAS in cortex (sTWAS, $P=6.66 \times 10^{-7}$, Z=-4.97) predicted a decreased preference for the *TMEM106B* 294 splice junction chr7:12224385-12229679 with the increased FTLD-TDP A GWAS risk, while 295 296 we also observed methylation OTL (mOTL) coloc hits for two CpGs for TMEM106B (~500 bp upstream cg23422036 coloc PPH4=94.25% and intronic cg09613507 coloc PPH4=94.09%) 297 (Supplementary Tables 12, 8). We summarized our gene prioritization results in Fig. 2 for 298 299 the genome-wide significant loci and a selection of the suggestive loci (with genes having GWAS evidence of $P \le 5 \times 10^{-6}$ in 1 Mb extended regions), and full results are presented in 300

301 Supplementary Tables 3-13 and Supplementary Fig. 2-5.

302 Next, we performed gene ontology analyses on tier1 prioritized genes. The most significant 303 term in the nominated genes in FTLD-TDP All was positive regulation of defense response to bacterium ($P=3.21 \times 10^{-5}$). Lysosomal function appeared to be strongly affected in FTLD-TDP 304 305 A with several genes such as GRN and TMEM106B (lysosomal organization GO term, 306 $P=4.12 \times 10^{-4}$) as well as cathepsin B (CTSB). We further detected enriched terms for retrograde 307 transport in FTLD-TDP B ($P=2.21\times10^{-3}$) driven by DENND2A and VPS53 genes and for excitatory postsynaptic potential in FTLD-TDP C (p=1.48x10⁻³) driven by DMPK and P2RX5 308 309 genes (Fig. 3, Supplementary Table 14). Importantly, except for lysosomal transport, no 310 terms overlapped between subtypes of FTLD-TDP, suggesting mostly distinct genetic etiologies in the different FTLD-TDP groups. 311

To further characterize genetic factors associated with FTLD-TDP, we performed gene-based analyses on common variants with $P < 10^{-5}$ using MAGMA. Analyses of FTLD-TDP All did not yield exome-wide significant loci; however, FTLD-TDP A showed exome-wide significant signals for the two genes located at the *GRN* locus (*FAM171A2*, *ITGA2B*) and for *TMEM106B* ($P=4.74\times10^{-7}$). The *TMEM106B* signal was driven by the rs10281425 variant (OR=0.54,

- $P=2.12 \times 10^{-7}$). No exome-wide significant signal was detected for the other two FTLD-TDP
- 318 pathological subtypes.

319 Expression of the top suggestive signals in cell types and brain regions

To find tissues and cell types for which gene expression profiles were enriched for genes within 320 321 FTLD-risk loci, we combined gene-based association statistics calculated using MAGMA with 322 gene expression patterns from the Genotype–Tissue Expression (GTEx) project in a gene set 323 enrichment analysis. We observed an enrichment in genes expressed in brain tissue 324 (cerebellum, frontal cortex, and cortex) in FTLD-TDP A and B. This was strikingly different 325 from the signature observed in FTLD-TDP C for which significant enrichment was only 326 detected in non-central nervous system tissue, in particular small intestine terminal ileum (Fig. 327 4, Supplementary Table 15). We also compared FTLD gene expression loci with similar data obtained from Alzheimer's disease and related disorders (ADRD)¹⁴ and ALS GWAS¹⁵. FTLD-328 329 TDP subtypes presented with a distinct genetic signature as compared to these related disorders 330 highlighting the importance of regional specificity in FTLD-TDP.

331 We subsequently queried PsychENCODE frontal-cortex single-cell RNA-seq datasets of 332 human-derived brain samples to specify further which brain-specific enriched cell types 333 express the genetic loci associated with FTLD-TDP risk (Fig. 4, Supplementary Table 16). 334 We observed a significant enrichment in genes expressed in excitatory neurons for FTLD-TDP A loci (Ex4 $P=3.55 \times 10^{-2}$, Ex5b $P=2.72 \times 10^{-2}$), and FTLD-TDP B loci (Ex8 $P=1.27 \times 10^{-4}$), while 335 no other cell type reached significance. While FTLD-TDP C loci were also significantly 336 enriched in genes expressed in excitatory neurons (Ex3e $P=2.10 \times 10^{-2}$), they were additionally 337 338 enriched in genes expressed in astrocytes and oligodendrocyte progenitor cells ($P=4.69 \times 10^{-2}$, 339 $P=2.53\times10^{-2}$). Genes expressed in microglia were enriched only in ADRD gene loci $(P=1.90 \times 10^{-2})$. Overall, loci comprising genes expressed in excitatory neurons were enriched 340

341	in the three FTLD-TDP subtypes with stronger specificity for specific neuron types in each
342	FTLD-TDP subtype as compared to what was observed for ALS gene loci.

343 UNC13A and TNIP1 loci

344 To provide further support for the identified FTLD-TDP risk loci, we performed a meta-345 analysis of our FTLD-TDP cohort with the Dementia-seq study (phs001963.v1.p1) that 346 includes 2,102 clinical FTLD patients and 1,748 controls. Given that this cohort lacks details 347 on the FTLD pathology underlying each patient, pathological subgroup analyses could not be 348 performed. Meta-analysis confirmed UNC13A and identified the new TNIP1 locus as genome-349 wide significantly associated with FTLD ($P_{rs12973192}=8.85 \times 10^{-10}$; $P_{rs871269}=3.42 \times 10^{-8}$, 350 respectively). Note that the most significant single nucleotide variant (SNV) at the UNC13A locus was rs12608932 (p=9.13x10⁻¹¹), in strong LD with rs12973192 (r²=0.96 D'=0.99). 351

Both *UNC13A* and *TNIP1* were previously associated with other neurodegenerative diseases^{14,16}. Colocalization analyses showed that our *UNC13A* signal was shared with ALS (coloc PPH4=95.71%), strongly confirming the genetic overlap between both diseases (**Fig. 5A**). Interestingly, for *TNIP1* we found strong colocalization with the ADRD association signal^{14,16} (coloc PPH4=99.2%) while its colocalization with ALS was weaker (71.5%), which was confirmed in a specificity analysis (coloc PPH4=20.1%, for p12=10e-06), possibly reflecting multiple independent association signals in FTLD in this locus (**Fig. 5B-C**).

359 **Rare variant analysis**

To identify genes carrying rare variants contributing to FTLD-TDP, we performed a burden test in genes with variants likely to affect protein function. In the overall FTLD-TDP cohort, no exome wide significant gene was detected (**Supplementary Table 17**). We did detect five exome-wide significant signals within FTLD-TDP pathological subtypes (**Table 3**, **Supplementary Table 18**). *TBK1* was associated with disease status in FTLD-TDP A and B ($P=1.27 \times 10^{-11}$, $P=3.17 \times 10^{-12}$, respectively). The signal was driven by 3 carriers in FTLD-TDP

366 A patients (3/193=1.5%) and 5 carriers in FTLD-TDP B patients (5/288=1.7%). We also 367 detected an enrichment in rare variants in VIPR1 in FTLD-TDP B (P=4.65e-07, 3/288 FTLD-TDP B and 1/3153 control; Fig. 6) and 2 exome wide significant signals in FTLD-TDP C 368 L3MBTL1 (P=2.87x10⁻⁷, 8/467 FTLD-TDP C and 3/3153 controls) and RBPJL (P=6.39x10⁻⁷, 369 370 5/467 FTLD-TDP C and 3/3153 controls). Weighted gene coexpression network analysis using the ROSMAP dataset and the BrainExp database¹⁷ revealed that L3MBTL1 and RBPJL 371 module (vellow, $P_{L3MBTLI}=1.32 \times 10^{-45}$, $P_{RBPJL}=1.00 \times 10^{-79}$; 372 belonged to the same 373 Supplementary Figure 6) that is enriched in neuroactive ligand-receptor interaction and the cytokine-cytokine receptor interaction gene-ontology terms ($P_{FDR}=3.7 \times 10^{-12}$, $P_{FDR}=5.8 \times 10^{-12}$, 374 375 respectively). While expression of L3MBTL1 was throughout the central nervous system cells, 376 RBPJL expression was restricted to inhibitory neurons and in particular to Parvalbumin 377 neurons (Supplementary Figure 6).

378 **Discussion**

In this work, we report 8 new genome-wide significant FTLD-TDP risk loci and 3 new genes 379 380 harboring rare variants contributing to FTLD-TDP risk, by performing the largest FTLD-TDP 381 WGS study to date, including 985 patients and 3,153 controls. A comprehensive analysis of 382 our data highlights the genetic overlap between FTLD-TDP, ADRD, and ALS while also 383 defining tissue and cell type enrichment unique to FTLD-TDP. Most importantly, we highlight 384 distinct genetic aetiologies for each of the three main FTLD-TDP pathological subtypes (A, B and C) suggesting that multiple distinct pathomechanisms underlie the TDP-43 dysfunction 385 386 and deposition in FTLD-TDP (Fig. 7).

We confirm and replicate for the first time our previously reported GWAS signal at the *UNC13A* locus in FTLD-TDP patients¹¹. The *UNC13A* risk haplotype tagged by rs12973192 and rs12608932 was previously shown to increase cryptic splicing of *UNC13A* in brain tissue by modulating TDP-43 binding^{18,19}. The cryptic splicing leads to transcripts with premature

391 stop codons and the subsequent loss of UNC13A protein, significantly impacting the release 392 of vesicles in glutamatergic synapses²⁰. Since *UNC13A* thus represents a shared risk factor 393 between ALS and FTLD-TDP additional genetic or environmental mechanisms likely drive 394 disease presentation.

395 We further establish and replicate a novel genetic association between the TNIP1 locus and 396 FTLD-TDP. Recently, Restuadi et al. deeply characterized the GPX3/TNIP1 locus associated 397 with ALS and suggested that GPX3 should be prioritized for deeper exploration into disease mechanisms related to this region²¹. GPX3, encoding for glutathione peroxidase 3, is a secreted 398 399 enzyme involved in the regulation of oxidative damage, and its levels were found to be reduced in ALS sera²². Interestingly, however, the risk variant associated with FTLD-TDP (rs871269) 400 401 is an expression quantitative trait locus for TNIP1 in the dorsolateral prefrontal cortex, and 402 along with the fact that we only observed a weak colocalization signal with the ALS locus, we 403 highlight TNIP1 as the most likely gene candidate for FTLD-TDP. In fact, we observed a 404 shared signal at this locus between our FTLD-TDP GWAS and the recent large ADRD GWAS¹⁴, suggesting genetic and/or clinical overlap between AD and FTLD-TDP. TNIP1 is a 405 406 ubiquitin-binding adaptor protein that regulates cell death and innate immune response through NF-kb activation²³⁻²⁵. TNIP1 undergoes phosphorylation by TBK1 and interacts with OPTN²⁶, 407 two proteins associated with FTLD-TDP etiology^{12,27}. While this functional connection further 408 409 supports *TNIP1* as FTLD-TDP risk gene, more work is needed to understand the mechanisms 410 underlying disease onset. Overall, we substantiate the genetic overlap between ALS, ADRD, 411 and FTLD-TDP and emphasize the need for deeper exploration into pathways underlying 412 disease-specific risk.

413 One of the most striking conclusions from this phase II FTLD-TDP GWAS is the distinct 414 association signals among FTLD-TDP pathological subtypes. Even the *UNC13A* and *TNIP1* 415 risk loci, which reach genome-wide significance in the meta-analysis stage, show stronger

416 association in FTLD-TDP B alone, and for the first time, genome-wide significant common

417 risk loci are reported for each of the individual pathological FTLD-TDP subtypes.

418 In FTLD-TDP A, in addition to individual genome-wide significant common variants assigned 419 to GRN, TINAG, MZT1, and FARP2 risk loci, we identified exome-wide significant association 420 with the burden of common variants in GRN and TMEM106B, in addition to multiple QTL-421 based analyses prioritizing TMEM106B as a tier 1 risk gene, re-enforcing the specific 422 connection of these genes with FTLD-TDP A, even in patients without loss-of-function GRN mutations^{11,28}. While *GRN* and *TMEM106B* are also reported as AD risk genes¹⁴, an even 423 424 stronger connection exists between these genes and limbic-predominant age-related TDP-43 encephalopathy (LATE)^{29,30}, which has a more restricted neuroanatomical distribution of TDP-425 426 43 pathology as compared to FTLD-TDP but with some characteristics of FTLD-TDP type A^{31,32}. The *TMEM106B* signal is primarily influenced by rs10281425, a variant located in the 427 3'UTR of TMEM106B, which tags the previously reported TMEM106B risk haplotype³³ 428 associated with an increase in TMEM106B mRNA expression³³ and a higher burden of 429 insoluble disease-associated TMEM106B C-terminal fragments³⁴. More broadly, also 430 431 including prioritized genes from the subthreshold regions, gene ontology analysis in FTLD-TDP A revealed enrichment in genes implicated in lysosomal function driven by GRN, 432 433 TMEM106B but also CSTB, three genes which also had the highest individual gene scores in 434 the prioritization analysis in FTLD-TDP A. CSTB encodes one of the most abundant lysosomal proteases in the brain³⁵, and has been reported as a progranulin protease^{36,37}. Genes involved 435 436 in lysosomal dysfunction were also overrepresented in FTLD-TDP B, including GRN and 437 *PPT1*. PPT1, is a lysosomal enzyme which facilitates the degradation of fatty-acylated proteins 438 by lysosomal hydrolases. Mutations in *PPT1* cause neuronal ceroid lipofuscinosis 1^{38,39} and 439 *Ppt1* knock-out mice displayed fewer lipid droplets (LD) than wild type, indicating impairment of lipophagy, previously associated with FTLD/ALS⁴⁰⁻⁴³. Overall, our genetic data provides 440

441 compelling evidence that lysosomal dysfunction contributes to the pathobiology of FTLD-TDP442 A, and, to a lesser extent FTLD-TDP B.

443 For FTLD-TDP B, additionally, we identified individual genome-wide significant associations 444 with variants in the *RCL1* and *PDS5* loci, and we observed enrichment for gene ontology terms 445 related to retrograde transport resulting from the VPS53 and DENND2A loci. VPS53 is part of the Golgi-associated retrograde protein (GARP) complex^{44,45} involved in intracellular 446 cholesterol transport by targeting NPC2 to lysosomes⁴⁶. Recently, laser capture 447 microdissection and single-cell mass spectrometry-based proteomics in motor neurons of ALS 448 449 patients revealed a strong reduction in endolysosomal trafficking complexes such as the GARP complexes⁴⁷. Limited information about DENN2A function is currently available, but 450 451 structural and functional analysis indicates it may be involved in intracellular vesicle trafficking to the lysosome and to the Golgi through its guanine nucleotide exchange factor 452 activity and regulation of RAB family GTPases⁴⁸. However, retrograde transport has been 453 previously implicated in ALS with, for instance, mutations in DCTN1^{49,50} and KIF5A^{51,52}, 454 highlighting functional connections of prioritized genes from the subthreshold loci with TDP-455 456 43 dysfunction and ALS. Future GWAS with larger sample sizes, potentially combining 457 FTLD-TDP B and ALS, are required to firmly establish a genetic contribution of this pathway 458 to disease.

Focusing on rare variants, exome-wide significant association with *TBK1* was observed in both FTLD-TDP A and B (but not FTLD-TDP C), confirming *TBK1* mutations as the most common cause of FTLD-TDP after *GRN* and *C9orf72*¹². We further unveiled rare predicted pathogenic variants associated with FTLD-TDP B within *VIPR1*, which encodes for the vasoactive intestinal peptide receptor 1. The variants are predicted to lead to an alteration of VIPR1 function, impairing the vasoactive intestinal peptide (VIP) biological pathway. Indeed, VIPR1 is activated upon binding by VIP, which exerts a neuroprotective effect mainly through glial 466 cells^{53,54} even though neurons also express VIPRs^{55,56}. Notably, VIP is also a key regulator of 467 innate and adaptive immunity⁵⁷, making it an important therapeutic target for multiple 468 neurodegenerative diseases. Altogether, our studies suggest that lysosome dysfunction and/or 469 alterations in the innate and adaptive immune system are important contributors to both FTLD-470 TDP A and B risk, yet to varying degrees in each pathological subtype and with likely 471 important variability in the contribution from each pathway among individual patients.

472 FTLD-TDP C was previously recognized as a clinicopathological entity distinct from FTLD-TDP A and B^{58} , and our genetic studies support this notion showing no overlap in common or 473 474 rare risk genes with the other FTLD-TDP types. Importantly, however, while often considered a sporadic FTLD subtype^{13,59,60}, we implicate several genes and risk loci in FTLD-TDP C and 475 476 uncover a potential role for mitochondrial membrane dysfunction and the notch signaling 477 pathway. C19orf52 (TIMM29), which mediates the import and insertion of multi-pass 478 transmembrane proteins into the mitochondrial inner membrane, was identified as the first 479 genome-wide significant risk locus for FTLD-TDP C. Rare-variant burden analyses further 480 associated rare predicted pathogenic variants in the RBPJL gene with FTLD-TDP C. RBPJL 481 encodes for the recombination signal binding protein for immunoglobulin kappa J region like 482 transcription factor. RBPJL is able to repress Notch target gene expression (Hey1, Hey2, HeyL and Notch3)⁶¹. As such, our findings align with a previous analysis of sub-genome-wide 483 significant genes in clinical svPPA patients, enriched in FTLD-TDP C, which highlighted an 484 overrepresentation of the Notch pathway⁶². Interestingly *RBPJL* and *L3MBTL1*, the second 485 486 gene carrying rare predicted pathogenic variants in FTLD-TDP C, are part of the same co-487 expression module, suggesting that they are functionally related. Moreover, L3MBTL1, a 488 histone methyl-lysine binding protein, is a key regulator of proteotoxicity associated with C9orf72 dipeptide repeats and mutant $SOD1^{63}$ and was found to be increased in spinal cord of 489 490 ALS patients. Furthermore, reduction of L3MBTL1 expression in drosophila models with the

491 C9orf72-associated dipeptides poly(PR) or poly(GR) ameliorated the rough-eye phenotype⁶³, 492 suggesting that loss of L3MBTL1 expression is beneficial. While no RNA samples were 493 accessible from rare variant carriers, nonsense-mediated decay escape has been reported in 494 other genes linked to ALS^{64} . It is thus possible that the *L3MBTL1* variants lead to the generation 495 of truncated proteins with toxic gain-of-function, but additional work is necessary to 496 understand the disease etiology fully.

497 When analyzed in sum, common variants associated with the different FTLD-TDP pathological 498 subtypes appeared to be located in genes expressed in excitatory neurons in contrast to AD risk 499 variants, which are enriched in microglia. Interestingly, glutamatergic transmission impairment has been reported in FTLD⁶⁵⁻⁶⁹ and voxel-based brain changes have been significantly 500 501 associated with spatial distribution of mGluR5 in symptomatic C9orf72 and GRN carriers⁷⁰. 502 Therefore, and in line with previously reported studies, our data suggest that neurons are the 503 major players in disease etiology, as compared to what has been observed in ADRD. 504 Interestingly, the distribution of risk loci was specific to the cerebellar hemisphere and the 505 frontal-cortex for both FTLD-TDP A and B, as opposed to FTLD-TDP C where genes 506 expressed in small intestine were enriched in risk loci. While the link between gut microbiome 507 and FTLD remains limited⁷¹, our data suggest that the gut-brain axis might be of interest for 508 future studies. In fact, emerging evidence also supports a role for the gut-brain axis in autoimmune diseases⁷², a group of disorders that were found to be enriched in svPPA patients⁷³. 509

In prior studies, besides UNC13A, common variants in the HLA and DPP6 loci were reported
to be associated with FTLD^{11,13}. The HLA-DR5 locus was identified as associated with clinical
FTLD but was not replicated in phase I of our International FTLD-TDP WGS Consortium.
HLA-DQA2 and DPP6 loci were reported as overall FTLD-TDP risk loci in phase I¹¹ but were
not replicated in the current study. The relative composition of patients with FTLD-TDP
pathological subtypes in phase I and II (e.g., less FTLD-TDP A in phase II) and inclusion of

516 clinically diagnosed individuals in phase II may have contributed to this; however, it is also 517 possible that the increase in sample size reduced type I errors from phase I. Importantly, we 518 did identify and replicate in two independent cohorts the UNC13A and TNIP1 loci associated 519 with FTLD-TDP. Replication of the newly identified risk loci, each specific to distinct 520 neuropathological FTLD-TDP subtypes, will require additional GWAS studies in the future. 521 Obtaining sufficient samples will, however, be challenging, especially for FTLD-TDP A, 522 which lacks a clear clinical correlate of the pathological phenotype. Functional characterization 523 of the newly identified genes and loci may also provide mechanistic insight.

524 In conclusion, we confirmed UNC13A and identified 8 new genetic loci, i.e. TNIP1, GRN, 525 TINAG, MZT1, FARP2, RCL1, PDS5B, and C19orf52, and 3 new genes with rare variants 526 associated with FTLD-TDP risk, i.e. VIPR1, RBPJL, and L3MBTL1. By enriching in 527 neuropathologically confirmed patients and substantially increasing our cohort size, we gained important knowledge in our understanding of FTLD-TDP pathophysiology. The recognition 528 529 that individual FTLD-TDP subtypes could in fact be considered separate diseases with distinct 530 pathomechanisms has significant implications for the design of clinical trials and therapeutic 531 interventions.

532

533 Methods

534 **Samples**

535 Our current dataset includes previously generated data through the International FTLD-TDP 536 WGS consortium phase I¹¹ with 554 persons with clinicopathologically defined FTLD-TDP 537 and newly generated phase II sequencing data from 32 FTLD-TDP A, 43 FTLD-TDP B, 66 538 FTLD-TDP C, 4 FTLD-TDP E, and 9 with unclassifiable FTLD-TDP pathology (abbreviated 539 as FTLD-TDP U, **Supplementary Table 19**). To increase statistical power, we also sequenced 540 70 persons with clinical diagnosis of bvFTD/ALS, a clinical subtype associated with FTLD-

541 TDP B, and 283 persons with svPPA, a clinical subtype associated with FTLD-TDP C. Overall, 542 the total cohort pre-quality control was a combined FTLD-TDP cohort of 202 FTLD-TDP A, 543 237 FTLD-TDP B, 225 FTLD-TDP C, 4 FTLD-TDP D, 11 FTLD-TDP E, 29 FTLD-TDP U 544 persons, 70 persons with bvFTD/ALS and 283 persons with svPPA. All persons clinically or 545 pathologically diagnosed with FTLD are referred to as patients throughout the manuscript. We further used WGS data from 982 participants from the Mayo Clinic Biobank (from phase I)^{11,74}, 546 322 new controls free of neurodegenerative disorder from Mayo Clinic with WGS available, 547 548 and 2,037 controls derived from the Alzheimer's disease sequencing project (ADSP). C9orf72 549 repeat expansions were assessed in all patients using our previously reported two-step protocol and Sanger sequencing was used to perform mutation analyses of $GRN^{7,9}$. Patients with 550 551 C9orf72 repeat expansion and LOF mutations in GRN were removed prior to WGS. Study 552 protocols were reviewed and approved by the appropriate institutional review boards.

553 Whole genome sequencing

554 In phase I of the International FTD-TDP WGS consortium, WGS was generated on 554 patients with FTLD-TDP (512 passed QC in that study)¹¹. Briefly, whole blood- or brain-derived DNA 555 556 from 499 unrelated FTLD-TDP patients and 982 participants from the Mayo Clinic Biobank 557 Study were sequenced at HudsonAlpha using the standard library preparation protocol using 558 NEBNext® DNA Library Prep Master Mix Set for Illumina® (New England BioLabs Inc., 559 Ipswich, MA, USA), Concentration of the libraries was assessed by Qubit® 2.0 Fluorometer, 560 and the quality of the libraries was estimated by a DNA 5 K chip on a Caliper GX. Accurate 561 quantification was determined using the qPCR-based KAPA Biosystems Library 562 Quantification kit (Kapa Biosystems, Inc., Woburn, MA, USA). Each sample was sequenced on one lane of Illumina's HiSeq X instrument using v2 flow cells and reagents to target 30× 563 564 genomic coverage. Fastq files previously generated on an Illumina HiSeq X for 55 FTLD-TDP 565 patients were obtained from 3 sites: UCSF (n = 36), DZNE (n = 14) and NSW (n = 5). In phase

566 II, additional WGS of 507 patients with FTLD-TDP, svPPA, bvFTD/ALS and 322 controls 567 free of neurodegenerative disorders was performed at USUHS sequencing center or Mayo Clinic Rochester using the TruSeq DNA PCR-Free Library preparation Kit (Illumina) followed 568 569 by Whole Genome Sequencing by synthesis (SBS) chemistry on HiSeq X Illumina platform 570 using the HiSeq X Ten Reag. kit v2.5. For all patients and controls, fastq files were transferred 571 to Mayo Clinic and processed through the Mayo Genome GPS v4.0 pipeline in batches of up 572 to 75 samples. Briefly, reads were mapped to the human reference sequence (GRCh38 build) 573 using the Burrows–Wheeler Aligner, and local realignment around indels was performed using 574 the Genome Analysis Toolkit (GATK). Variant calling was performed using GATK 575 HaplotypeCaller followed by variant recalibration (VQSR) according to the GATK best 576 practice recommendations. At the time of analysis, participants from the Mayo Clinic Biobank with possible clinical diagnosis or family history of a neurodegenerative disorder were 577 578 removed. We also included genotypic data (vcf) from 2,037 controls from the Alzheimer's 579 Disease Sequencing Project, leading to a total of 1,061 patients and 3,341 controls.

580 Sample level quality control and definition of subgroups

581 Samples with less than $30 \times$ coverage in more than 50% of the genome, call rate below 85%, 582 sex error, contamination defined by a FREEMIX score above 4 or non-Caucasian ethnicity 583 were removed. At this step, joint genotyping on all samples was performed, a final relatedness measurement was calculated using PREST⁷⁵, and duplicates were removed, while only one 584 585 individual per family was kept. In total, 985 pathologically confirmed FTLD-TDP or presumed 586 FTLD-TDP patients clinically presenting with svPPA or bvFTD/ALS, as well as 3,153 587 neurologically normal controls passed all quality control measures (Supplementary Table 1). 588 Age at onset of svPPA and bvFTD/ALS did not differ from the age at onset of FTLD-TDP C 589 (P=1) and FTLD-TDP B patients (P=1), respectively. Based on these findings and the 590 previously established associations between the svPPA and bvFTD/ALS clinical diagnoses

591 with specific FTLD-TDP pathological subtypes, we combined svPPA with FTLD-TDP C and 592 bvFTD/ALS with FTLD-TDP B patients in all analyses. Within our overall cohort of 193 593 FTLD-TDP A, 288 FTLD-TDP B (defined as FTLD-TDP B and bvFTD/ALS) and 467 FTLD-TDP C (defined as FTLD-TDP C and svPPA), the ages at onset and death differed significantly 594 595 between the pathological FTLD-TDP subtypes (Table 2; Supplementary Figure 1). FTLD-596 TDP A patients had a later age at onset than FTLD-TDP B and FTLD-TDP C groups $(P=4.73 \times 10^{-8}, P=1.37 \times 10^{-13}, \text{respectively})$, and a later age at death $(P=4.00 \times 10^{-15}, P=3.00 \times 10^{-15})$ 597 ⁶, respectively). FTLD-TDP B had an earlier age at death as compared to FTLD-TDP C 598 599 $(P=5.60 \times 10^{-8})$. Differences in age distribution in between patient groups were assessed using 600 the Kruskal-Wallis test followed by Wilcoxon test correcting for multiple testing. Corrected P 601 are provided.

602 Variant level quality control

603 Genotype calls with genotype quality (GQ) < 20 and/or depth (DP) < 10 were set to missing, 604 and variants with edit-distance >4 and call rate < 80% were removed from all subsequent 605 analyses leading to a total of 85,345,466 variants. For all analyses, only variants that pass 606 VQSR (127,658 variants removed) and with a call rate >95% in cases or controls were 607 considered (591,431 variants removed). Functional annotation of variants was performed using 608 ANNOVAR (version2016Feb01). Rare loss of function variants (frameshift 609 insertion/deletion/block substitution, stopgain, stoploss and splicing single nucleotide 610 variants—SNVs) identified in exome-wide significant associated genes in the rare variant 611 analyses (Supplementary Table 17) were confirmed in patients by Sanger sequencing 612 (primers available upon request). For the known neurodegenerative disease genes (GRN, MAPT, TBK1, OPTN, VCP, TARDBP, CHCHD10, SQSTM1, UBQLN2, hnRNPA1, 613 614 hnRNPA2B1, CSF1R, FUS, CHMP2B, and LRRK2), potentially pathogenic rare variants were 615 also identified and confirmed by Sanger sequencing (n=25; Supplementary Table 20).

616 **Generation of principal components**

Prior to running genetic association analyses, principal component (PC) analysis was performed using a subset of variants meeting the following criteria: minor allele frequency (MAF)>5% and full sample Hardy–Weinberg Equilibrium (HWE) $P>1x10^{-5}$. Influential regions such as the *HLA* region were removed, and variants were pruned by linkage disequilibrium with r² threshold of 0.1 prior to PC analysis. This analysis identified 13 PCs that were significantly associated with patient/control status, which were subsequently used as covariates in all genetic association analyses.

624 Variant-level analysis of common variants

For the common variant GWAS, single nucleotide variants (SNV) with MAF>0.01 in patients or controls (n=7,178,250 variants) and HWE $P>1.00x10^{-6}$ in controls were analyzed (17,450 variants removed). In addition, since whole genome sequencing of FTLD-TDP patients and controls was performed at multiple sites, a test was performed to identify variants with significant differences in genotype distributions between sequencing batches, and 592,701 SNVs showing evidence of batch effects (p<0.05) were removed leading to a total of 6,568,099 variants analyzed.

632 For all remaining variants, association of genotypes with the patient/control status was assessed 633 using logistic regression with allele dosage as the predictor assuming log-additive allele effects. 634 Sex and the first thirteen PCs were included as covariates in the models. The SNV-level analyses were performed using PLINKv.00a23LM2 combining all FTLD-TDP cases (FTLD-635 636 TDP All) and in FTLD-TDP pathological subtypes. Meta-analyses of FTLD-TDP phase II with 637 publicly available dataset from the Dementia-seq project (phs001963.v2.p1) was performed 638 under a fixed-effects model comparing our data with 2,102 FTLD cases and 1,748 controls from the Dementia-seq project using Metal⁷⁶. Dementia-seq vcf were processed the exact same 639

way as our data except that 10 PCs were included in the model to perform common variantassociation analysis.

642 **Colocalization analyses**

643 We performed colocalization analysis for UNC13A and TNIP1 loci (top SNVs ±100 kb) with ALS (GCST90027164) and ADRD (GCST90027158) using the 'coloc' package version 4.0.4 644 645 in R using our meta-analyses data. When the summary statistics of the other trait was expressed 646 on another build than GRCh38, the variant alleles and positions were converted. We set the prior probabilities to $\pi 1 = 1 \times 10^{-4}$, $\pi 2 = 1 \times 10^{-4}$ and $\pi 12 = 1 \times 10^{-5}$ for a causal variant in trait 1 647 648 or trait 2 and a shared causal variant between traits 1 and 2, respectively (default parameters). 649 Sensitivity analysis was performed at $\pi 12=1 \times 10^{-6}$. P <0.05 was considered statistically 650 significant.

651 Tissue and cell type enrichment analysis

Tissue and cell type enrichment analyses were performed using the summary statistics and 652 653 FUMA. Briefly, FUMA aggregates summary statistics per gene to calculate gene-wise 654 association signals using MAGMA version 1.6 and subsequently tests whether tissues and cell 655 types are enriched for expression of these genes. For tissue enrichment analysis, we used the 656 GTEx version 8 reference set. P < 0.05 across all tissues (n = 54) were considered statistically 657 significant. For cell type enrichment analyses, we used human-derived single-cell RNA-seq 658 data from major brain cell types (PsychENCODE). Excitatory and inhibitory neurons from the PsychENCODE dataset were labeled based on their transcriptional profile from 1 to 8⁷⁷. 659 *P*<0.05 were considered statistically significant. 660

661 Gene prioritization and functional interpretation of GWAS

We performed the gene prioritization and functional interpretation analyses for FTLD-TDP Alland each FTLD-TDP pathological subtype separately by using the subtype-specific GWAS

summary statistics. We adapted a systematic gene prioritization and functional interpretation

strategy (as previously described in Bellenguez et al.¹⁴) to prioritize GWAS-implicated 665 666 candidate risk genes and nominate possible downstream biological mechanisms. Briefly, six distinct domains, that are related to lead variant annotation and molecular QTL-GWAS 667 668 integration analyses (e.g., colocalization and TWAS) in FTLD-relevant tissues and cell types 669 were systematically assessed: (1) variant annotation, (2) eQTL-GWAS integration, (3) sQTL-670 GWAS integration, (4) protein expression QTL (pQTL)-GWAS integration, (5) mQTL-GWAS 671 integration, and (6) histone acetylation QTL (haQTL)-GWAS integration; for which detailed 672 information on categories and subcategories is provided in Supplementary Table 2.

673 In the variant annotation domain, for each lead variant at each locus, we queried which 674 candidate risk genes were the nearest protein-coding genes with respect to the genomic position 675 of the lead variants, and/or whether the lead variant was a rare (MAF < 1% in gnomAD v4 non-676 Finnish European samples) and/or protein-altering (missense or predicted LOF) variant for the 677 same nearest protein-coding genes. In the molecular QTL-GWAS integration domains, we 678 leveraged molecular cis-QTL catalogues for different molecular phenotypes (i.e., gene 679 expression, splicing, protein expression, methylation, and histone acetylation) in FTLD-680 relevant tissues and cell types, we performed genetic colocalization analyses between 681 molecular cis-QTL and GWAS signals, TWAS, and proteome-wide association studies 682 (PWAS). For these analyses, we processed and used publicly available molecular QTL catalogues; namely, FTLD-relevant bulk brain regions from AMP-AD⁷⁸⁻⁸¹ (as reanalyzed in 683 Bellenguez et al.¹⁴) and GTEx v8⁸² cohorts for the bulk brain eQTLs and sQTLs, eight major 684 685 brain cell types (excitatory neurons, inhibitory neurons, astrocytes, oligodendrocytes, 686 microglia, oligodendrocyte precursor cells/committed oligodendrocyte precursors [OPCs/COPs], pericytes, and endothelial cells) from Bryois et al.⁸³ and primary microglia from 687 Young et al.⁸⁴ and the MiGA study⁸⁵ for the brain cell-type-specific eQTLs (ct-eQTL) and for 688 689 microglia sQTLs (from the MiGA study), dorsolateral prefrontal cortex (DLPFC) pQTLs from

Wingo et al.⁸⁶ (v2), and DLPFC mQTLs and haQTLs from Brain xQTL serve (June 2021 690 691 release)^{86,87}. Finally, we also included naïve state monocyte and macrophage eQTL catalogues⁸⁸⁻⁹³ reanalyzed by eQTL Catalogue (Release 6)⁹⁴ and lymphoblastoid cell line 692 (LCL) eOTLs from GTEx v8⁸² and the European Alzheimer & Dementia Biobank (EADB) 693 Belgian LCL cohorts¹⁴. Using each of these molecular QTL catalogues, we first investigated 694 695 whether the reported lead variants in this study were significant molecular QTLs for the 696 quantified levels of molecular phenotypes in tissues and cell types of interest. Moreover, for 697 each quantified molecular phenotype in these catalogues we performed molecular QTL-GWAS 698 coloc (v5.2.2) analyses to determine if specific molecular QTL signals are colocalized (at coloc 699 PP4 \geq 70%) with FTLD subtype GWAS signals. Finally, we conducted TWAS (using FUSION) 700 and S-PrediXcan [implemented in MetaXcan] tools) for each heritable feature modelled in gene expression (eTWAS; followed by eTWAS fine mapping with FOCUS⁹⁵ [v0.803] within 1 Mb 701 702 extended genome-wide significant lead variant genetic regions in each FTLD-TDP subtype GWAS), splicing (sTWAS), and PWAS reference panels derived from AMP-AD bulk brain⁷⁸⁻ 703 ⁸¹, GTEx bulk brain and LCL⁸², EADB Belgian LCL¹⁴, and Wingo et al. DLPFC data⁸⁶, to 704 705 identify the significant associations (after Bonferroni correction) between predicted levels of 706 gene expression, splicing, and protein expression with each FTLD subtype-specific genetic 707 risk. Detailed description and details (e.g., number of samples, significance criteria, references 708 and sources) of these molecular QTL catalogues used in this study for the systematic gene 709 prioritization strategy and functional interpretation of FTLD-TDP GWAS results can be found 710 in Supplementary Table 5.

Using a predetermined weighting scheme for each type of evidence (see Supplementary Table
3), we computed a gene prioritization score (between 0 and 87) for each gene which was
constructed by the weighted sum of the hits in different subcategories within six distinct
domains described above. As described in Bellenguez et al.¹⁴ in detail, we gave higher weights

715 for the hits obtained through the brain QTLs rather than other tissue QTLs, for the replicated 716 hits across multiple catalogues or reference panels, and for the fine-mapped eTWAS hits. After 717 obtaining weighted gene prioritization scores in each FTLD-TDP subtype-specific gene 718 prioritization analysis, we first assigned each candidate risk gene (with gene prioritization score 719 >0) to the genome-wide significant loci if their gene coordinates (based on GENCODE v24) 720 are positioned within a ± 1 Mb window of the identified lead variants (**Table 2**). The rest of the 721 candidate risk genes in subthreshold regions (nominated by coloc and TWAS analyses only) 722 were grouped together if they were positioned together (<1 Mb), and these subthreshold regions 723 were indexed and named as subthreshold loci. The candidate risk genes in genome-wide 724 significant and subthreshold loci were also annotated by the evidence of minimum P observed 725 within 1 Mb of the gene coordinates in related FTLD-TDP subtype-specific GWAS summary 726 statistics. We then ranked the protein-coding genes per locus in each FTLD subtype-specific 727 analysis based on their total weighted scores, and investigated the relative score differences 728 between the highest ranked protein-coding gene and the other candidate risk genes in each 729 locus, together with the overall total weighted score of the top-ranked gene. We then classified 730 candidate risk genes in each locus as tier 1 and tier 2 prioritized risk genes, respectively having 731 a higher and lower level of confidence for being a true risk gene in a given locus (see Bellenguez et al.¹⁴ for detailed description). As also described in Bellenguez et al.¹⁴, the gene 732 733 prioritization pipeline determines a single tier 1 prioritized risk gene in each locus if there is adequate evidence, meanwhile additional tier 2 prioritized risk genes in the same loci or 734 735 multiple tier 2 prioritized risk genes in a locus can also be assigned based on the score 736 distribution of candidate genes in the investigated loci.

737 Gene Ontology analyses

Gene ontology on tier 1 genes identified in FTLD-TDP All or in individuals FTLD-TDP
subtype analyses were performed using anRichment R package which aggregates summary

statistics and assesses gene ontology term enrichment. Gene ontology terms were collapsed using the rrvigo R package. Only terms with 2 or more genes were considered in the analyses. P < 0.05 was considered statistically significant.

743 Gene-level analysis of rare variants

Association of rare variants with the patient/control status was assessed using an unweighted 744 745 burden test implemented using the SKAT_1.2.1 R package. Only VQSR pass variants with call rate > 90%, ED \leq 4, and MAF < 0.01 in either patients or controls were included. We included 746 only frameshift (insertion/deletion/block substitution), stopgain, stoploss and splicing SNVs 747 748 (jointly defined as loss-of-function (LOF) variants), and non-synonymous SNVs with REVEL score above 0.75%. Sex and the first thirteen PCs were used as covariates. Genome-wide 749 significance was defined as $P < 5x10^{-8}$ and exome-wide significance as a p value $< 2.5x10^{-6}$ 750 751 (Bonferroni correction for 20,000 genes).

752 RBPJL and L3MBTL1 RNA expression

Assessment of module membership of *RBPJL* and *L3MBTL1* was performed using the gene co-expression analysis from the BrainEXP-NPD¹⁷ website using default parameters. Single nuclei RNA expression was assessed using the transcriptomic comparative viewer if the Seattle Alzheimer's Disease Brain cell Atlas from middle temporal gyrus of 84 aged donors (42 cognitively normal and 42 with dementia).

758 Data Availability

759 Summary statistics will be available on dbGAP platform post publication.

760 Datasets and molecular QTLs used in the gene prioritization are publicly available (see also

761 **Supplementary Table 4**):

- 762 eQTLs and eTWAS reference panels in AD-relevant bulk brain regions from AMP-AD
- cohorts and in LCLs from the EADB Belgian cohort, as analyzed by Bellenguez et
- 764 al.¹⁴: <u>https://doi.org/10.5281/zenodo.5745927;</u>
- 765 sQTLs and sTWAS reference panels in AD-relevant bulk brain regions from AMP-AD
- cohorts and in LCLs from the EADB Belgian cohort, as analyzed by Bellenguez et
- 767 al¹⁴.: <u>https://doi.org/10.5281/zenodo.5745929;</u>
- 768 Bryois et al.⁸³ ct-eQTL catalogues (<u>https://doi.org/10.5281/zenodo.5543734</u>);
- 769 eQTL Catalogue database (<u>https://www.ebi.ac.uk/eqtl/</u>);
- 770 Brain xQTL serve mQTL and haQTL catalogues
- 771 (<u>https://mostafavilab.stat.ubc.ca/xqtl/xQTL_updated_data/</u>);
- 772 GTEx v8 eQTL and sQTL catalogues (<u>https://www.gtexportal.org/</u>);
- 773 GTEx v8 expression and splicing prediction models for eTWAS/sTWAS
- 774 (https://predictdb.org/post/2021/07/21/gtex-v8-models-on-eqtl-and-sqtl/#mashr-based-
- 775 <u>models</u>);
- 776 MiGA eQTLs (<u>https://doi.org/10.5281/zenodo.4118605</u>);
- 777 MiGA sQTLs (<u>https://doi.org/10.5281/zenodo.4118403</u>);
- 778 MiGA meta-analysis (<u>https://doi.org/10.5281/zenodo.4118676</u>); and
- Wingo et al.⁸⁶ pQTLs v2 (<u>https://www.synapse.org/#!Synapse:syn23627957</u>).

780

781 **References**

782	1.	Rascovsky, K. et al. Sensitivity of revised diagnostic criteria for the behavioural
783		variant of frontotemporal dementia. Brain 134, 2456-77 (2011).
784	2.	Gorno-Tempini, M.L. et al. Classification of primary progressive aphasia and its
785		variants. Neurology 76 , 1006-14 (2011).
786	3.	Lee, E.B. et al. Expansion of the classification of FTLD-TDP: distinct pathology
787		associated with rapidly progressive frontotemporal degeneration. Acta Neuropathol
788		134 , 65-78 (2017).
789	4.	Mackenzie, I.R. <i>et al.</i> A harmonized classification system for FTLD-TDP pathology.
790		Acta Neuropathol 122, 111-3 (2011).
791	5.	Mackenzie, I.R. et al. Heterogeneity of ubiquitin pathology in frontotemporal lobar
792		degeneration: classification and relation to clinical phenotype. Acta Neuropathol 112,
793		539-49 (2006).
794	6.	Mackenzie, I.R. & Neumann, M. Reappraisal of TDP-43 pathology in FTLD-U
795		subtypes. Acta Neuropathol 134, 79-96 (2017).
796	7.	Baker, M. et al. Mutations in progranulin cause tau-negative frontotemporal dementia
797		linked to chromosome 17. <i>Nature</i> 442, 916-9 (2006).
798	8.	Cruts, M. et al. Null mutations in progranulin cause ubiquitin-positive frontotemporal
799		dementia linked to chromosome 17q21. Nature 442, 920-4 (2006).
800	9.	DeJesus-Hernandez, M. et al. Expanded GGGGCC hexanucleotide repeat in
801		noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron
802		72 , 245-56 (2011).
803	10.	Renton, A.E. et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of
804		chromosome 9p21-linked ALS-FTD. Neuron 72, 257-68 (2011).
805	11.	Pottier, C. et al. Genome-wide analyses as part of the international FTLD-TDP
806		whole-genome sequencing consortium reveals novel disease risk factors and increases
807		support for immune dysfunction in FTLD. Acta Neuropathol 137, 879-899 (2019).
808	12.	Pottier, C. et al. Whole-genome sequencing reveals important role for TBK1 and
809		OPTN mutations in frontotemporal lobar degeneration without motor neuron disease.
810		Acta Neuropathol 130, 77-92 (2015).
811	13.	Ferrari, R. et al. Frontotemporal dementia and its subtypes: a genome-wide
812		association study. Lancet Neurol 13, 686-99 (2014).
813	14.	Bellenguez, C. et al. New insights into the genetic etiology of Alzheimer's disease and
814		related dementias. Nat Genet 54, 412-436 (2022).
815	15.	Project Min, E.A.L.S.S.C. Project MinE: study design and pilot analyses of a large-
816		scale whole-genome sequencing study in amyotrophic lateral sclerosis. Eur J Hum
817		<i>Genet</i> 26 , 1537-1546 (2018).
818	16.	Benyamin, B. et al. Cross-ethnic meta-analysis identifies association of the GPX3-
819		TNIP1 locus with amyotrophic lateral sclerosis. <i>Nat Commun</i> 8 , 611 (2017).
820	17.	Jiao, C. et al. BrainEXP: a database featuring with spatiotemporal expression
821		variations and co-expression organizations in human brains. <i>Bioinformatics</i> 35 , 172-
822		174 (2019).
823	18.	Brown, A.L. et al. TDP-43 loss and ALS-risk SNPs drive mis-splicing and depletion
824		of UNC13A. <i>Nature</i> 603 , 131-137 (2022).
825	19.	Ma, X.R. <i>et al.</i> TDP-43 represses cryptic exon inclusion in the FTD-ALS gene
826	• •	UNC13A. <i>Nature</i> 603 , 124-130 (2022).
827	20.	Augustin, I., Rosenmund, C., Sudhof, T.C. & Brose, N. Munc13-1 is essential for
828		fusion competence of glutamatergic synaptic vesicles. <i>Nature</i> 400 , 457-61 (1999).

829 21. Restuadi, R. et al. Functional characterisation of the amyotrophic lateral sclerosis risk 830 locus GPX3/TNIP1. Genome Med 14, 7 (2022). 831 22. Tanaka, H. et al. ITIH4 and Gpx3 are potential biomarkers for amyotrophic lateral 832 sclerosis. J Neurol 260, 1782-97 (2013). 833 Oshima, S. et al. ABIN-1 is a ubiquitin sensor that restricts cell death and sustains 23. 834 embryonic development. Nature 457, 906-9 (2009). 835 24. Su, Z. et al. ABIN-1 heterozygosity sensitizes to innate immune response in both 836 RIPK1-dependent and RIPK1-independent manner. Cell Death Differ 26, 1077-1088 837 (2019). 838 25. Zhou, J. et al. A20-binding inhibitor of NF-kappaB (ABIN1) controls Toll-like 839 receptor-mediated CCAAT/enhancer-binding protein beta activation and protects 840 from inflammatory disease. Proc Natl Acad Sci U S A 108, E998-1006 (2011). 841 26. Lee, Y. et al. Coordinate regulation of the senescent state by selective autophagy. Dev 842 Cell 56, 1512-1525 e7 (2021). 843 Freischmidt, A. et al. Haploinsufficiency of TBK1 causes familial ALS and fronto-27. 844 temporal dementia. Nat Neurosci 18, 631-6 (2015). 845 28. Mackenzie, I.R. et al. The neuropathology of frontotemporal lobar degeneration 846 caused by mutations in the progranulin gene. Brain 129, 3081-90 (2006). 847 29. Katsumata, Y. et al. Multiple gene variants linked to Alzheimer's-type clinical 848 dementia via GWAS are also associated with non-Alzheimer's neuropathologic 849 entities. Neurobiol Dis 174, 105880 (2022). 850 30. Katsumata, Y., Nelson, P.T., Ellingson, S.R. & Fardo, D.W. Gene-based association 851 study of genes linked to hippocampal sclerosis of aging neuropathology: GRN, TMEM106B, ABCC9, and KCNMB2. Neurobiol Aging 53, 193 e17-193 e25 (2017). 852 853 Nelson, P.T. et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): 31. 854 consensus working group report. Brain 142, 1503-1527 (2019). 855 32. Josephs, K.A. et al. Pathological, imaging and genetic characteristics support the 856 existence of distinct TDP-43 types in non-FTLD brains. Acta Neuropathol 137, 227-857 238 (2019). 858 33. Van Deerlin, V.M. et al. Common variants at 7p21 are associated with frontotemporal 859 lobar degeneration with TDP-43 inclusions. Nat Genet 42, 234-9 (2010). 860 34. C, T.V. et al. C-terminal TMEM106B fragments in human brain correlate with 861 disease-associated TMEM106B haplotypes. Brain 146, 4055-4064 (2023). Hook, V. et al. Cathepsin B in neurodegeneration of Alzheimer's disease, traumatic 862 35. 863 brain injury, and related brain disorders. Biochim Biophys Acta Proteins Proteom 864 1868, 140428 (2020). 865 36. Lee, C.W. et al. The lysosomal protein cathepsin L is a progranulin protease. Mol 866 Neurodegener 12, 55 (2017). 867 37. Zhou, X. et al. Lysosomal processing of progranulin. Mol Neurodegener 12, 62 868 (2017). 869 Vesa, J. et al. Mutations in the palmitoyl protein thioesterase gene causing infantile 38. 870 neuronal ceroid lipofuscinosis. Nature 376, 584-7 (1995). 871 Camp, L.A., Verkruyse, L.A., Afendis, S.J., Slaughter, C.A. & Hofmann, S.L. 39. 872 Molecular cloning and expression of palmitoyl-protein thioesterase. J Biol Chem 269, 873 23212-9 (1994). 874 Branchu, J. et al. Loss of spatacsin function alters lysosomal lipid clearance leading to 40. 875 upper and lower motor neuron degeneration. Neurobiol Dis 102, 21-37 (2017). 876 41. Han, S.M. et al. VAPB/ALS8 MSP ligands regulate striated muscle energy 877 metabolism critical for adult survival in caenorhabditis elegans. PLoS Genet 9, 878 e1003738 (2013).

879	42.	Cingolani, F. & Czaja, M.J. Regulation and Functions of Autophagic Lipolysis.
880		Trends Endocrinol Metab 27, 696-705 (2016).
881	43.	Liu, Y. et al. A C9orf72-CARM1 axis regulates lipid metabolism under glucose
882		starvation-induced nutrient stress. Genes Dev 32, 1380-1397 (2018).
883	44.	Conibear, E. & Stevens, T.H. Vps52p, Vps53p, and Vps54p form a novel
884		multisubunit complex required for protein sorting at the yeast late Golgi. Mol Biol
885		<i>Cell</i> 11 , 305-23 (2000).
886	45.	Liewen, H. et al. Characterization of the human GARP (Golgi associated retrograde
887		protein) complex. Exp Cell Res 306, 24-34 (2005).
888	46.	Wei, J. et al. The GARP Complex Is Involved in Intracellular Cholesterol Transport
889		via Targeting NPC2 to Lysosomes. Cell Rep 19, 2823-2835 (2017).
890	47.	Guise, A.J. et al. TDP-43-stratified single-cell proteomic profiling of postmortem
891		human spinal motor neurons reveals protein dynamics in amyotrophic lateral
892		sclerosis. <i>bioRxiv</i> (2023).
893	48.	Yoshimura, S., Gerondopoulos, A., Linford, A., Rigden, D.J. & Barr, F.A. Family-
894		wide characterization of the DENN domain Rab GDP-GTP exchange factors. J Cell
895		<i>Biol</i> 191 , 367-81 (2010).
896	49.	Deshimaru, M. et al. DCTN1 Binds to TDP-43 and Regulates TDP-43 Aggregation.
897		Int J Mol Sci 22 (2021).
898	50.	He, J., Yu, W., Liu, X. & Fan, D. An identical DCTN1 mutation in two Chinese
899		siblings manifest as dHMN and ALS respectively: a case report. Amyotroph Lateral
900		Scler Frontotemporal Degener 23, 149-153 (2022).
901	51.	Nicolas, A. et al. Genome-wide Analyses Identify KIF5A as a Novel ALS Gene.
902		<i>Neuron</i> 97 , 1267-1288 (2018).
903	52.	Xia, C.H. et al. Abnormal neurofilament transport caused by targeted disruption of
904		neuronal kinesin heavy chain KIF5A. J Cell Biol 161, 55-66 (2003).
905	53.	Brenneman, D.E., Hauser, J., Spong, C.Y. & Phillips, T.M. Chemokines released
906		from astroglia by vasoactive intestinal peptide. Mechanism of neuroprotection from
907		HIV envelope protein toxicity. Ann N Y Acad Sci 921, 109-14 (2000).
908	54.	Brenneman, D.E. et al. Vasoactive intestinal peptide. Link between electrical activity
909		and glia-mediated neurotrophism. Ann N Y Acad Sci 897, 17-26 (1999).
910	55.	Chneiweiss, H., Glowinski, J. & Premont, J. Vasoactive intestinal polypeptide
911		receptors linked to an adenylate cyclase, and their relationship with biogenic amine-
912		and somatostatin-sensitive adenylate cyclases on central neuronal and glial cells in
913		primary cultures. J Neurochem 44, 779-86 (1985).
914	56.	Hosli, E. & Hosli, L. Autoradiographic localization of binding sites for vasoactive
915		intestinal peptide and angiotensin II on neurons and astrocytes of cultured rat central
916		nervous system. <i>Neuroscience</i> 31 , 463-70 (1989).
917	57.	Delgado, M. & Ganea, D. Vasoactive intestinal peptide: a neuropeptide with
918		pleiotropic immune functions. Amino Acids 45, 25-39 (2013).
919	58.	Baer, G.M. et al. Sporadic FTLD TDP type C is a distinct clinicopathological entity
920		from FTLD types A/B (\$7.007). Neurology 88, \$7.007 (2017).
921	59.	Rohrer, J.D. et al. The heritability and genetics of frontotemporal lobar degeneration.
922		<i>Neurology</i> 73 , 1451-6 (2009).
923	60.	Snowden, J., Neary, D. & Mann, D. Frontotemporal lobar degeneration: clinical and
924		pathological relationships. Acta Neuropathol 114, 31-8 (2007).
925	61.	Pan, L. et al. Transcription Factor RBPJL Is Able to Repress Notch Target Gene
926		Expression but Is Non-Responsive to Notch Activation. Cancers (Basel) 13(2021).

927	62.	Bonham, L.W. <i>et al.</i> Genetic variation across RNA metabolism and cell death gene
928		networks is implicated in the semantic variant of primary progressive aphasia. Sci Rep
929	\mathcal{C}^{2}	9 , 10854 (2019).
930	63.	Lu, J. <i>et al.</i> L3MBTL1 regulates ALS/FTD-associated proteotoxicity and quality
931	<i>с</i> 1	control. Nat Neurosci 22, 875-886 (2019).
932	64.	Guissart, C. <i>et al.</i> Premature termination codons in SODI causing Amyotrophic
933		Lateral Sclerosis are predicted to escape the nonsense-mediated mRNA decay. Sci
934	~ •	<i>Rep</i> 10 , 20/38 (2020).
935 936	65.	Murley, A.G. & Rowe, J.B. Neurotransmitter deficits from frontotemporal lobar degeneration <i>Brain</i> 141 (1263-1285) (2018)
937	66	Ferrer, I. Neurons and their dendrites in frontotemporal dementia. <i>Dement Geriatr</i>
938	001	Cogn Disord 10 Suppl 1 , 55-60 (1999)
939	67	Premi E <i>et al</i> Unravelling neurotransmitters impairment in primary progressive
940	07.	aphasias Hum Brain Mapp 44 2245-2253 (2023)
941	68	Bowen DM <i>et al.</i> Imbalance of a serotonergic system in frontotemporal dementia:
942	00.	implication for pharmacotherapy <i>Psychopharmacology</i> (<i>Berl</i>) 196 603-10 (2008)
943	69	Procter A W Ourne M & Francis P T Neurochemical features of frontotemporal
944	07.	dementia Dement Geriatr Coon Disord 10 Suppl 1 80-4 (1999)
945	70	Premi E <i>et al</i> Early neurotransmitters changes in prodromal frontotemporal
946	70.	dementia: A GENEI study <i>Neurophial Dis</i> 179 106068 (2023)
947	71	Ghezzi I. Cantoni C. Rotondo F. & Galimberti D. The Gut Microbiome-Brain
9/8	/1.	Crosstalk in Neurodegenerative Diseases <i>Biomedicines</i> 10 (2022)
9/9	72	Khawar M M Sr <i>et al.</i> The Gut-Brain Axis in Autoimmune Diseases: Emerging
050	12.	Insights and Therapeutic Implications. Curaus 15, e48655 (2023)
951	73	Miller 7 A <i>at al</i> TDP-13 frontotemporal lobar degeneration and autoimmune
952	15.	disease I Neurol Neurosurg Psychiatry 84 956-62 (2013)
953	74	Olson I.F. <i>et al.</i> The Mayo Clinic Biobank: a building block for individualized
954	/ 4.	medicine Mayo Clin Proc 88, 952-62 (2013)
955	75	McDeek M S & Sun I Statistical tests for detection of misspecified relationships by
956	15.	use of genome-screen data Am I Hum Canat 66 1076-94 (2000)
957	76	Willer C I Li V & Abecasis G R METAL: fast and efficient meta-analysis of
958	70.	genomewide association scans. <i>Bioinformatics</i> 26 , 2190-1 (2010)
950	77	Lake B.B. at al. Integrative single cell analysis of transcriptional and epigenetic
939	//.	states in the human adult brain. Nat Riotachnol 36 , 70, 80 (2018)
900	79	Allen M <i>et al.</i> Human whole genome genetyne and transcriptome data for
901	70.	Alzheimer's and other neurodegenerative diseases. Sci Data 3 , 160080 (2016)
902	70	Alzheimer S and other neurodegenerative diseases. Sci Data 3, 100009 (2010). Mostafavi S at al. A molecular network of the aging human brain provides insights
905	19.	into the pathology and cognitive decline of Alzheimer's disease. Nat Neurosci 21
904		11 910 (2019)
905	80	011-019 (2010). Pennett D.A. et al. Policious Orders Study and Push Memory and Aging Project L
900	ðŪ.	Alphoimang Dig 64, \$161, \$180 (2018)
907	01	Wong M et al. The Mount Sinci schort of large scale genemic transcriptomic and
900	01.	waig, W. et al. The Would Shiai conort of large-scale genomic, transcriptonic and
909	0 7	Consortium G.T. The GTEx Consortium atlas of genetic regulatory affects across
970	02.	human tissuas. Saignas 260 , 1219, 1220 (2020)
9/1	02	numan ussues. Science 309 , 1516-1550 (2020).
912 072	03.	novel risk gapon for nevering and neurological disorders. Not Neuropsi 25, 1104
713 074		1112 (2022)
7/4 075	Q <i>1</i>	1112 (2022). Voung AMH at al A man of transprintional haterogeneity and regulatory variation
976	04.	in human microglia. Nat Genet 53, 861-868 (2021).

977	85.	Lopes, K.P. et al. Genetic analysis of the human microglial transcriptome across brain
978		regions, aging and disease pathologies. Nat Genet 54, 4-17 (2022).
979	86.	Wingo, A.P. et al. Integrating human brain proteomes with genome-wide association
980		data implicates new proteins in Alzheimer's disease pathogenesis. Nat Genet 53, 143-
981		146 (2021).
982	87.	Ng, B. et al. An xQTL map integrates the genetic architecture of the human brain's
983		transcriptome and epigenome. Nat Neurosci 20, 1418-1426 (2017).
984	88.	Alasoo, K. et al. Shared genetic effects on chromatin and gene expression indicate a
985		role for enhancer priming in immune response. Nat Genet 50, 424-431 (2018).
986	89.	Nedelec, Y. et al. Genetic Ancestry and Natural Selection Drive Population
987		Differences in Immune Responses to Pathogens. Cell 167, 657-669 e21 (2016).
988	90.	Chen, L. et al. Genetic Drivers of Epigenetic and Transcriptional Variation in Human
989		Immune Cells. Cell 167, 1398-1414 e24 (2016).
990	91.	Momozawa, Y. et al. IBD risk loci are enriched in multigenic regulatory modules
991		encompassing putative causative genes. Nat Commun 9, 2427 (2018).
992	92.	Quach, H. et al. Genetic Adaptation and Neandertal Admixture Shaped the Immune
993		System of Human Populations. Cell 167, 643-656 e17 (2016).
994	93.	Fairfax, B.P. et al. Innate immune activity conditions the effect of regulatory variants
995		upon monocyte gene expression. Science 343, 1246949 (2014).
996	94.	Kerimov, N. et al. A compendium of uniformly processed human gene expression and
997		splicing quantitative trait loci. Nat Genet 53, 1290-1299 (2021).
998	95.	Mancuso, N. et al. Probabilistic fine-mapping of transcriptome-wide association
999		studies. Nat Genet 51, 675-682 (2019).
1000	96.	Ioannidis, N.M. et al. REVEL: An Ensemble Method for Predicting the Pathogenicity
1001		of Rare Missense Variants. Am J Hum Genet 99, 877-885 (2016).
1002		
1003		
1005		
1004		
1005		
1005		

1006 **Declarations**

1007 Ethics approval and consent to participate

1008 This study was approved by the appropriate Mayo Clinic Institutional Review Board.

1009 Consent for publication

1010 Not applicable.

1011 **Competing interests**

1012 RR and IRM receive royalties from progranulin-related patent.

1013 **Funding**

- 1014 This work was made possible by the support of funding from the UG3/UH3 NS103870, P30
- 1015 AG062677, P01 AG003949, R01 AG037491, P01 NS084974, R01 AG37491, R01 DC12519,
- 1016 R21 NS94684, R01 DC010367, P30 AG062422, P01 AG019724, U01 AG057195, U19
- 1017 AG063911, P30 AG077444, P30 AG013854, P30 AG07297, P30 AG066468, P30
- 1018 AG012300, P30 AG072972, P30 AG010129, P50 AG005136, P30 AG066509, P30
- 1019 AG066511, P01 AG066597, P30 AG072979, R01 AG077444, and R01 DC008552.
- 1020 Supported by the ALLFTD Consortium (U19: AG063911, funded by the NIA and NINDS) and the former ARTFL & LEFFTDS Consortia (ARTFL: U54 NS092089, funded by the 1021 1022 NINDS and NCATS; LEFFTDS: U01 AG045390, funded by the NIA and NINDS). 1023 Supported by the Mayo ADRC (P30 AG62677, funded by the NIA). A subset of samples 1024 were obtained through the National Centralized Repository for Alzheimer Disease and 1025 Related Dementias (NCRAD), which receives government support under a cooperative 1026 agreement grant (U24 AG021886) awarded by the National Institute on Aging (NIA), were 1027 used in this study. The work was supported by Mayo Clinic Center for Regenerative 1028 Medicine, the gifts from the Donald G. and Jodi P. Heeringa Family, the Haworth Family 1029 Professorship in Neurodegenerative Diseases fund, The Albertson Parkinson's Research 1030 Foundation, and PPND Family Foundation.

1031 This work was supported by TARGET ALS, the Rainwater Charitable Foundation and the 1032 Bluefield Project to Cure FTD, the DEC Brain and BioBank, CIHR grant 74580, the 1033 Canadian Consortium on Neurodegeneration in Aging, of the Canadian Institutes of Health

Research, the University of Pittsburgh Brain Institute. This work was supported by the NIHR
UCL/H Biomedical Research Centre, the UK MRC (MR/M008525/1; MR/M023664/1), the
Bluefield Project and the JPND (2019-02248). This work was made possible, in part, by the
Winspear Family Center for Research on the Neuropathology of Alzheimer disease, the
McCune Foundation, and the Nancy and Buster Alvord endowment.

- 1039 Research was supported by Grants provided by Swedish FTD Initiative- Schörling foundation,
- 1040 the Swedish research Council (Dnr 521-2010-3134, 529-2014-7504, 2015-02926), Alzheimer
- 1041 Foundation Sweden, Brain Foundation Sweden, Swedish Brain Power, Gamla Tjänarinnor,
- 1042 Stohnes Foundation, Dementia Foundation Sweden and the Stockholm County Council (ALF-
- 1043 project). The brain pathology was provided through in part by the Brain Bank at Karolinska
- 1044 Institutet which was financially supported by Karolinska Institutet StratNeuro, Swedish Brain
- 1045 Power, Stockholm County Council core facility funding (CG) and Schörling Foundation.
- 1046 This work was supported in part by SAO-FRA 2021/0032. FK receives a postdoctoral
- 1047 fellowship (BOF 49758) from the University of Antwerp Research Fund.

1048 Acknowledgements

We thank the Mayo Clinic Center of Individualized Medicine for collection and sequencing of
the Mayo Clinic Biobank samples. CG would also like to acknowledge Dr Inger Nennesmo for
the neuropathological characterization. Acknowledgment for the ADSP dataset can be found
in Supplementary Notes.

1053

1054

1055

1056 Legends

Figure 1: Genome-wide association study on common variants. A Manhattan plot of the FTLD-TDP All patients versus controls association study. **B** Manhattan plot of the FTLD-TDP A patients versus controls association study. **C** Manhattan plot of the FTLD-TDP B patients versus controls association study. **D** Manhattan plot of the FTLD-TDP C patients versus controls association study. The red-dotted line represents the genome-wide significance level $(p = 5x10^{-8})$.

1063 Figure 2: Gene prioritization results for FTLD-TDP subgroups. A visual summary of 1064 weighted evidence category scores for the prioritized genes within genome-wide significant 1065 and subthreshold loci with candidate genes whose 1 Mb extended gene coordinates contain a minimal GWAS P evidence of $\leq 5 \times 10^{-6}$ in related FTLD subtype-specific GWAS summary 1066 1067 statistics. Using the gene prioritization strategy in these selected loci, we prioritized a total of 1068 25 genes in 23 loci at two different confidence levels (10 tier 1 and 15 tier 2 prioritized genes). 1069 The leftmost squares which are colored in red for FTLD-TDP A, in blue for FTLD-TDP B, and 1070 in green for FTLD-TDP C specific analyses indicate the locus index numbers which contain 1071 additional "S" patterns for the subthreshold loci, whereas others indicate the genome-wide 1072 significant loci. The types of evidence for each category are colored according to the six different domains to which they belong. Weighted scores for each evidence category are 1073 1074 rescaled to a 0-100 scale based on the maximum score a candidate gene can obtain from a 1075 category (see Supplementary Table 2). The darker colors represent higher scores in 1076 categories, while tier 1 prioritized genes are displayed in dark green and tier 2 prioritized genes 1077 are displayed in light green. Only tier 1 and tier 2 genes are shown for each locus, and all 1078 candidate genes considered and scored can be found in Supplementary Table 3. MAFs (based 1079 on gnomAD v4 non-Finnish European samples) and CADD (v1.7) PHRED scores for rare 1080 and/or protein-altering rare variants are labeled in white within the respective squares. eQTL,

expression QTL; sQTL, splicing QTL; mQTL, methylation QTL; pQTL, protein-expression
QTL; haQTL, histone acetylation QTL; coloc, colocalization; eTWAS, expression
transcriptome-wide association study; sTWAS, splicing transcriptome-wide association study;
PWAS, proteome-wide association study; Mon. Mac., monocytes and macrophages; LCL,
lymphoblastoid cell line; QTLCat, The eQTL Catalogue.

Figure 3: Top 5 Gene Ontology terms enriched in FTLD-TDP subgroups. Hierarchical GO
 analysis of biological process terms considering genes in genetic loci prioritized for FTLD TDP All, FTLD-TDP A, FTLD-TDP B and FTD-TDP C.

1089 Figure 4: Enrichment of brain regions and cell types in FTLD subgroups. A Enrichment 1090 of genes in multiple tissues, including 13 brain regions, and based on GTEX data in FTLD 1091 subgroups, ADRD and ALS. Color represents the enrichment coefficient, and size indicates 1092 two-sided -log10 (FDR adjusted *P*s) of enrichment obtained by the linear regression model in 1093 the MAGMA gene property analysis. **B** Central nervous system cell type enrichment analyses 1094 in FTLD subgroups, ADRD and ALS. Color represents the enrichment coefficient, and size 1095 indicates two-sided –log10 (FDR adjusted *Ps*) of enrichment obtained by the linear regression model in the MAGMA gene property analysis. Excitatory neurons and glial cells are 1096 1097 highlighted in blue. Excitatory and inhibitory neurons from the PsychENCODE dataset were 1098 labeled based on their transcriptional profile from 1 to 8. Asterisks denote brain regions or cell 1099 types enriched with FDR P < 0.05. Cx, cortex; Ex*, Excitatory neuron, In*, inhibitory neurons; 1100 Oligo, oligodendrocytes; OPCs, oligodendrocyte progenitor cells; Astro, astrocytes; Endo, 1101 endothelial cells; Per, pericytes.

Figure 5: Locus zoom plots for UNC13A and TNIP1 loci. A Genetic colocalization between
the UNC13A locus in FTLD-TDP (meta-analysis) and ALS signal. B Genetic colocalization
between the TNIP1 locus in FTLD-TDP (meta-analysis) and ALS. C Genetic colocalization

between the *TNIP1* locus in FTLD-TDP (meta-analysis) and ADRD. For **A**, **B** and **C**, chromosome position is located on the x axis and $-\log 10(P)$ is represented on the y axis. Each dot represents a SNV tested in the dataset for its association with disease status. Purple diamonds are the index SNVs reported. Linkage disequilibrium with index SNV is indicated by r².

Figure 6: Rare loss of function and predicted pathogenic variants in proteins associated with FTLD. Schematic representation of VIPR1, L3MBTL1 and RBPL protein structure (source Uniprot) showing a map of nonsense, splicing, frameshift and missense with a REVEL score>0.75 rare variants in patients and controls. Variants identified in patients are colored in orange, variants identified in controls are colored in blue. n=number of carriers.

1115

1116 Figure 7: Schematic representation of findings from the International FTLD-TDP WGS 1117 phase II. Genome-wide significant single variant loci, exome-wide significant genes, enriched 1118 gene ontology pathways and tissues- and cell-types enriched for genome-wide significant risk 1119 loci are shown for each FTLD-TDP pathological subtype in rings moving from the center 1120 (genome-wide significant single variant loci in FTLD-TDP All) to the outer rings. Orange 1121 background shades correspond to FTLD-TDP A findings, green background shades to FTLD-1122 TDP B findings and blue background shades to FTLD-TDP C findings. Gene names in green 1123 font were exome-wide significant using a gene-based approach with common variants while 1124 gene names in red font were exome-wide significant using a gene-based approach with rare 1125 variants. In addition to unique associations, some overlap between FTLD-TDP A and B exist 1126 (TBK1, lysosomal function and inflammatory response), whereas FTLD-TDP C showed 1127 unique and non-overlapping genetic profile.

Table 1: Demographics after quality control.

	FTLD-TDP A	FTLD-TDP B	FTLD-TDP C	FTLD-TDP U^a	Control
Number	193	288	467	37	3,153
(% Female)	(42.49)	(38.89)	(48.61)	(40.54)	(56.71)
Age at onset or age at collection (Standard Deviation, years)	68.00 (10.52)	62.00 (10.76)	60.50 (8.05)	60.50 (8.74)	64.08 (14.31)
Age at death (Standard Deviation, years)	78.00 (11.72)	67.00 (10.90)	72.00 (7.32)	67.84 (9.41)	82.00 (8.41)
Disease duration (Standard Deviation, years)	7.30 (4.65)	4.00 (3.61)	11.00 (7.46)	6.50 (5.20)	NA
^a FTLD-TDP U = FTLD-TDP unclassifiable	•				

GROUP	rsID ^a	REF/ALT	LOCUS NAME ^b	GENOMIC POSITION ^c	ODDS RATIO (95% CI) ^d	Р	MAF PATIENTS/CONTROLS	NEW LOCUS
FTLD-TDP All	rs8111424	A/G	UNC13A	19:17640336	1.37 (1.24-1.54)	1.17X10 ⁻⁸	0.376/0.141	
FTLD-TDP A	rs5848	C/T	GRN	17:44352876	1.89 (1.52-2.34)	5.57X10 ⁻⁹	0.442/0.292	New
FTLD-TDP A	rs138698596	T/A	TINAG	6:54591659	5.22 (2.91-9.36)	3.01X10 ⁻⁸	0.045/0.009	New
FTLD-TDP A	rs138959102	C/T	MZT1	13:72499532	8.41 (3.95-17.88)	3.22X10 ⁻⁸	0.029/0.004	New
FTLD-TDP A	rs886815	G/A	FARP2	2:241457011	9.55 (4.26-21.41)	4.26X10 ⁻⁸	0.026/0.003	New
FTLD-TDP B	rs76742217	G/A	RCL1	9:4821273	9.31 (4.30-20.18)	1.55X10 ⁻⁸	0.023/0.003	New
FTLD-TDP B	rs12973192	G/C	UNC13A	19:17642430	1.74 (1.46-2.08)	8.52X10 ⁻¹⁰	0.484/0.346	
FTLD-TDP B	rs527749954	C/T	PDS5B	13:32620689	7.66 (3.71-15.84)	3.89X10 ⁻⁸	0.025/0.003	New
FTLD-TDP B	rs871269	C/T	TNIP1	5:151052827	0.55 (0.44-0.68)	4.72X10 ⁻⁸	0.206/0.322	New
FTLD-TDP C	rs576561313	C/T	C19orf52	19:10945440	13.11 (5.33-32.23)	2.03X10 ⁻⁸	0.014/0.001	New

^ars number, according to dbSNP build 153.

^bNearest protein-coding gene according to GENCODE release 33.

^cGRCh38 assembly.

^dApproximate OR calculated with respect to the alternative allele.

GROUP	GENE NAME	NUMBER OF PATIENTS	MAF ^a IN PATIENTS	NUMBER OF CONTROLS	MAF ^a IN CONTROLS	Р
FTLD-TDP A	TBK1	3	7.77X10 ⁻⁰³	0	0	1.27X10 ⁻¹¹
FTLD-TDP B	TBK1	5	8.68X10 ⁻⁰³	0	0	3.17X10 ⁻¹²
FTLD-TDP B	VIPR1	3	5.21X10 ⁻⁰³	1	1.59X10 ⁻⁰⁴	4.65X10 ⁻⁷
FTLD-TDP C	RBPJL	5	5.35X10 ⁻⁰³	3	4.76X10 ⁻⁰⁴	6.39X10 ⁻⁷
FTLD-TDP C	L3MBTL1	8	8.57X10 ⁻⁰³	3	4.76X10 ⁻⁰⁴	2.38X10 ⁻⁷

Table 3: Genes harboring rare variants associated with FTLD-TDP

"MAF = minor allele frequency



Category



GO Terms across Groups





Cell Type

A









